Tyligand Bioscience

Executive Summary

Tyligand Bioscience is a clinical-stage biotechnology company based in Shanghai, China, founded in 2020. The company specializes in structure-based drug design to develop novel small molecule therapeutics for oncology and immunology, with a focus on selective kinase inhibitors and other targeted therapies. Having raised $30 million, Tyligand is advancing a pipeline aimed at challenging cancer targets and autoimmune disorders. The company's approach leverages medicinal chemistry expertise to create highly selective molecules, potentially reducing off-target effects and improving therapeutic windows. As a private company in Phase 1 development, Tyligand represents an early-stage investment opportunity in the precision oncology and immunology space, with the potential to address significant unmet medical needs. However, the lack of publicly disclosed pipeline details and clinical data limits visibility into specific programs.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 trial for lead oncology candidate40% success
• H2 2026Presentation of preclinical data for lead autoimmune candidate60% success
• Q1 2027Regulatory filing for first IND in immunology indication50% success